Medical Technology and Devices (MTD) Group has successfully completed the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems (BGM) businesses, enhancing its position as the world’s second-largest player in the global pen needle market. The acquisition allows MTD to increase its production capacity to over 2.5 billion pen needles, solidifying its commitment to delivering superior diabetes and obesity care solutions globally.
The integration of Ypsomed’s businesses brings advanced technologies and brands to MTD’s diabetes and obesity product portfolio, allowing the company to offer a comprehensive range of solutions for both self-care and professional use. With exclusive products like G34, the thinnest and shortest pen needle on the market, MTD reaffirms its dedication to innovation in healthcare.
In addition to strengthening its presence in established markets like North America, Germany, and France, the acquisition enables MTD to enter new strategic markets such as China and India. This expansion, coupled with a significant investment in state-of-the-art production facilities in Europe, positions MTD for continued growth and success in the diabetes care industry.
CEO Charles Bouaziz expressed excitement about the transformative potential of the acquisition, emphasizing MTD’s focus on delivering high-quality solutions to customers and expanding its global reach. Supported by Studio Legale LCA for legal aspects, MTD is dedicated to advancing the future of diabetes care and empowering individuals to take control of their health.
MTD Group is a consumer healthcare organization with a leading portfolio of brands specializing in diabetes, sharp medical instruments, wound care, cardiac monitors, thermometers, and nebulizers. The company’s products reach over 100 markets worldwide, with a strong presence in EMEA, APAC, and North America. MTD’s extensive R&D division is committed to developing innovative technologies to meet the evolving needs of consumers and healthcare professionals.
With a focus on intuitive monitoring, painless medication administration, and easy-to-use solutions, MTD aims to provide peace of mind to individuals seeking to manage their health effectively. The Group’s growth and success are supported by a dedicated team and a commitment to maintaining the highest quality standards in all operations. To learn more about MTD Group and its diverse product portfolio, visit their website at http://www.mtdglobal.com.
Source link
